February 2025 - Exxel Pharma

Exxel Pharma Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
Exxel Pharma’s Innovative Small Molecule, EX937, Rapidly Advancing Toward First-In-Human Study for the Treatment of Refractory Chronic Cough